Product Roadmap

Our team has an robust plan to develop commercial products that leverage our All-In-One technology.

In 2024, we completed the development of a immunoassay kit for milk allergens and aflatoxins that is ready for commercialization.

In 2025, our goal is to finalize the prototyping of a fully quantitative All-In-One rapid test kit (lateral flow) which could be commercialized for both the human health and food safety markets. Concurrently, we are exploring partnerships with device manufacturers to develop a custom lateral flow reader.

By 2026, we aim to create a compact immunoassay automation device that is optimized for All-In-One. We expect this device to be significantly more efficient and affordable than competing products, increasing the addressable market for automation devices.